

# MARKET REPORT



## Ulcerative Colitis (UC) - Market Review, Epidemiology And Market Forecast - 2029

**BioPortfolio**

Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Ulcerative Colitis (UC) - Market Review, Epidemiology And Market Forecast - 2029

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com)

# Ulcerative Colitis (UC) - Market Review, Epidemiology And Market Forecast - 2029

FirstView Market Insight " Ulcerative colitis -Market Review, Epidemiology and Market Forecast - 2029" provides in depth understanding of historical and forecasted epidemiology along with the detailed market insights. The report covers detailed information on the disease, treatment algorithm, existing treatment and upcoming treatment regimens, unmet needs, market drivers, market barriers, sales trend and market revenue during study period 2018-2029.

Ulcerative colitis is an inflammatory bowel disease (IBD) that causes long-lasting inflammation and ulcers (sores) in your digestive tract. Ulcerative colitis affects the innermost lining of your large intestine (colon) and rectum. Symptoms usually develop over time, rather than suddenly. In the US, almost 3.1 million individuals (which is about 1.3 percent of the total country population) were either diagnosed with ulcerative colitis or Crohn's disease, according to the Center for Disease Control and Promotion (CDC). It is also estimated that almost 70,000 fresh of IBD are recorded annually in the United States. In response, the hospitalization rate has risen in America, generating opportunities in the market for the therapy of inflammatory bowel diseases. Besides this, the recent product approvals by the European Medicines Agency and other similar organizations have enabled the market gain significant momentum.

## Ulcerative colitis Overview

This report contains comprehensive overview of disease including disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends, as well as details about treatment algorithms and treatment guidelines for Ulcerative colitis

## Ulcerative colitis Epidemiology & Forecast

This section encompasses information on the incidence and prevalence of disease in EU5, US & Japan. It also provides historical, current and forecasted estimates of diagnosed/treatable patient population.

## Ulcerative colitis existing and upcoming treatment landscape

Captures the evolution of treatment paradigm including the current and emerging drug therapies. Provides information on the clinical trial results, mechanism of action, route of administration, therapeutic positioning, regulatory milestones and patent exclusivity. It gives insight into the potential therapeutic targets for drug development. The section also covers major events and latest happenings, deals and collaborations.

## Ulcerative colitis Market Size

This section of report will address the major issues, on the size and total addressable market share for Ulcerative colitis - Market Review, Epidemiology and Market Forecast - 2029. This will help the companies to understand and visualize their business prospects and make major decisions based on the historical, current and forecasted market share across the globe. Analyse the commercial potential of the product as well as the disease/therapy area.

## Ulcerative colitis Market Trends & Unmet needs

This section of the report helps to understand the market trend and opportunities by analysing the impact of current therapies on the market, current and future unmet needs, drivers and barriers and demand of better technology. This is determined by analysing the impact of various factors such as mechanism of action, route, cost of therapy, patient segmentation, existing available treatments, compliance and need of the market, expected launch timelines, competitors, brand value and KOLs perception.

## Additional Details

**Publisher** : First View Insight

**Reference** :

**Number of Pages** : 250

**Report Format** : PDF

**Publisher Information** :



Our systems go beyond providing extensive comprehensive studies. We inspire our clients to develop knowledgeable growth mechanisms. Our insights are precise and approved by peer-driven research methodology. In brief, we pay emphasis on the success stories of our clients. When assessing solutions, we focus entirely on enabling them to influence their true potential for growth.

### About FirstView Insight

FirstView Insight is a global market research and business consulting firm which focuses exclusively on healthcare domain. We help pharmaceutical companies to turn out to be progressively focused in a rapidly evolving market characterized by unpredictable product pipelines and uncertain regulatory actions.

# Table Of Contents for Ulcerative Colitis (UC) - Market Review, Epidemiology And Market Forecast - 2029

- 1. Disease overview1.1. Types1.2. Pathophysiology1.3. Symptoms1.4. Etiology1.5. Risk Factor1.6. Diagnosis1.7. Consensus panel recommendations for the evaluation and diagnosis of patients 2. Treatment Landscape2.1. List of Marketed Drugs2.1.1. Vedolizumab2.1.1.1. Product Profile2.1.1.2. Regulatory Milestones2.1.1.3. Advantages & Disadvantages2.1.1.4. Safety and Efficacy2.1.1.5. Side effects2.1.1.6. Unmet Need2.1.1.7. SWOT Analysis2.1.2 Adalimumab biosimilar2.1.2.1. Product Profile2.1.2.2. Regulatory Milestones2.1.2.3. Advantages & Disadvantages2.1.2.4. Safety and Efficacy2.1.2.5. Side effects2.1.2.6. Unmet Need2.1.2.7. SWOT AnalysisTo be continued2.2. List of Late stage products2.2.1. Mirikizumab2.2.1.1. Product Profile2.2.1.2. Regulatory Milestones2.2.1.3. Advantages & Disadvantages2.2.1.4. Safety and Efficacy2.2.1.5. Side effects2.2.1.6. Unmet Need2.2.1.7. SWOT Analysis2.2.2 Carotegrast methyl2.2.2.1. Product Profile2.2.2.2. Regulatory Milestones2.2.2.3. Advantages & Disadvantages2.2.2.4. Safety and Efficacy2.2.2.5. Side effects2.2.2.6. Unmet Need2.2.2.7. SWOT AnalysisTo be continued2.3. List of mid stage products2.3.1. E 60072.3.1.1. Product Profile2.3.1.2. Regulatory Milestones2.3.1.3. Advantages & Disadvantages2.3.1.4. Safety and Efficacy2.3.1.5. Side effects2.3.1.6. Unmet Need2.3.1.7. SWOT Analysis2.3.2 F8 IL102.3.2.1. Product Profile2.3.2.3. Regulatory Milestones2.3.2.3. Advantages & Disadvantages2.3.2.4. Safety and Efficacy2.3.2.5. Side effects2.3.2.6. Unmet Need2.3.2.7. SWOT AnalysisTo be continued2.4. List of early stage productsTo be continued3. Patent Information3.1. Patent Expiry in United States (US)3.2. Patent Expiry in European Union (EU)3.3. Patent Expiry in Japan4. Historical and Forecasted sales of marketed drugs5. Global Epidemiology - Forecasted to 20296. Current Epidemiology - Forecasted to 2029 by 7 Major Markets (7MM)6.1. Epidemiology of United States-20296.2. Epidemiology of United Kingdom-20296.3. Epidemiology of Germany-20296.4. Epidemiology of France-20296.5. Epidemiology of Spain-20296.6. Epidemiology of Italy-20296.7. Epidemiology of Japan-20296.8. Epidemiology of Emerging Markets-20297. Global Market size (2018-2029)7.1. Global Forecasted Market size (2018-2029)7.2. Global Market Size by Geography7.2.1. Market size of US (2014-2018)7.2.2. Forecasted Market size of US (2018-2029)7.2.3. Market size of Europe7.2.4. Market size of Germany (2014-2018)7.2.5. Forecasted Market size of Germany (2018-2029)7.2.6. Market size of United Kingdom (2014-2018)7.2.7. Forecasted Market size of United Kingdom (2018-2029)7.2.8. Market size of France (2014-2018)7.2.9. Forecasted Market size of France (2018-2029)7.2.10. Market size of Italy (2014-2018)7.2.11. Forecasted Market size of Italy (2018-2029)7.2.12. Market size of Spain (2014-2018)7.2.13. Forecasted Market size of Spain (2018-2029)7.2.14. Market size of Japan (2014-2018)7.2.15. Forecasted Market Size of Japan (2018-2029)7.2.16. Market size of Emerging Markets (2014-2018)7.2.17. Forecasted Market size of Emerging Markets (2018-2029)8. Market Trends9. Market Opportunity Assessment10. Drivers and Barriers11. Unmet Needs12. SWOT Analysis13. Appendix14. Report Methodology15. Consulting Services16. Disclaimer

# List Of Tables in Ulcerative Colitis (UC) - Market Review, Epidemiology And Market Forecast - 2029

Table 1: Incident Cases of Ulcerative Colitis (UC) in United States (2018-2029)

Table 2: List of Phase III Drugs for Ulcerative Colitis (UC)

Table 3: Vedolizumab Clinical Trials by Zone, 2019

Table 4: Adalimumab biosimilar Clinical Trials by Zone, 2019

Table 5: Mirikizumab Clinical Trials by Zone, 2019

Table 6: Carotegrast methyl Clinical Trials by Zone, 2019

Table 7: E 6007 Clinical Trials by Zone, 2019

Table 8: F8 IL10 Clinical Trials by Zone, 2019

Table 9: United States Market Size of in USD, Million (2018-2029)

# List Of Figures, Charts and Diagrams in Ulcerative Colitis (UC) - Market Review, Epidemiology And Market Forecast - 2029

Figure 1: Pathophysiology for Ulcerative Colitis (UC)

Figure 2: Risk Factors for Ulcerative Colitis (UC)

Figure 3: Etiology of Ulcerative Colitis (UC)

Figure 4: Incident Probable Cases of in United States (2018-2029)

Figure 5: Treatment Algorithm

Figure 6: Lines of Treatment

Figure 7: Incident Cases of Ulcerative Colitis (UC) in United States (2018-2029)

Figure 8: List of Phase III Drugs for Ulcerative Colitis (UC)

Figure 9: Vedolizumab Clinical Trials by Zone, 2019

Figure 10: Adalimumab biosimilar Clinical Trials by Zone, 2019

Figure 11: Mirikizumab Clinical Trials by Zone, 2019

Figure 12: Carotegrast methyl Clinical Trials by Zone, 2019

Figure 13: E 6007 Clinical Trials by Zone, 2019

Figure 14: F8 IL10 Clinical Trials by Zone, 2019

Figure 15: United States Market Size of in USD, Million (2018-2029)

# How to Buy...

Ulcerative Colitis (UC) - Market Review, Epidemiology And Market Forecast - 2029

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/239050>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com) We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$2975** | Single User Price
- \$5100** | Enterprise License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.